Adenine Base Editor Correcting PAH Mutation for PKU Cure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for phenylketonuria (PKU), such as dietary restrictions and medication, have limitations including poor compliance, nutritional deficiencies, and limited access, leading to impaired cognitive development and neuropsychiatric problems.
Innovation Solution
The use of adenine base editors (ABEs) to directly correct the c.1222C>T mutation in the PAH gene, which is the most common mutation associated with PKU, by contacting the PAH polynucleotide with a base editor complexed with guide polynucleotides to effect an A·T to G·C alteration, thereby restoring the wild-type sequence and correcting the disease phenotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dietary treatment is implemented for PKU, then intellectual disability is prevented, but compliance is poor and nutritional deficiencies occur
Solution Approach 1:
The patent replaces the mechanical/dietary intervention system with a genetic therapy system. Instead of requiring ongoing dietary restrictions and supplementation, the invention uses base editing technology to directly correct the PAH gene mutation, substituting continuous dietary management with a one-time genetic correction approach.
Solution Approach 2:
The base editor system enables self-service by correcting the genetic defect within the patient's own hepatocytes. The therapy uses the patient's liver cells to produce functional PAH enzyme, eliminating the need for external dietary intervention and supplementation.
2Reliability
If dietary treatment is implemented for PKU, then intellectual disability is prevented, but nutritional deficiencies particularly in vitamins D and B12 occur
Solution Approach 1:
The patent replaces the dietary management system that causes nutritional deficiencies with a genetic correction system. By restoring PAH enzyme function through base editing, the therapy eliminates the need for restrictive diets and associated vitamin supplements, thereby preventing nutritional deficiencies while maintaining cognitive protection.
3Duration of action of stationary object
If base editing therapy is used to correct PAH mutation, then durable cure is achieved, but treatment complexity increases
Solution Approach 1:
The base editing system is segmented into distinct functional modules: a guide RNA for target recognition, a Cas9 nickase for single-strand cutting, and an adenosine deaminase for base conversion. This modular segmentation allows each component to perform its specific function efficiently, simplifying the overall therapeutic approach despite the complexity of the genetic correction process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a durable cure for a subset of PKU patients by permanently correcting the causative mutation, potentially eliminating the need for lifelong treatment and improving cognitive and executive functioning.
Implementation Method 1
the adenosine deaminase domain, capable of deaminating adenosine in deoxyribonucleic acid (DNA)
Data Source
AI summary
Compositions and methods for effecting base editing to correct mutations in the phenylalanine hydroxylase gene, thereby curing phenylketonuria, are disclosed.